Literature DB >> 15526907

Anti-inflammatory effect of PPARgamma in cultured human mesangial cells.

Zuying Xiong1, Haichang Huang, Jingzi Li, Youfei Guan, Haiyan Wang.   

Abstract

Our aim is to investigate whether peroxisome proliferator-activator receptor-gamma (PPARgamma) expression was altered in human mesangial cells under inflammatory stress and whether PPARgamma could retard the inflammatory responses. Based on cultured human mesangial cell lines (HMCLs), PPARgamma expressions at protein and mRNA levels were observed by Western blot analysis and reverse transcriptase polymerase chain reaction. Informatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay. Our results demonstrated that PPARgamma protein expression was dramatically increased in HMCLs stimulated by IL-1beta (10 ng/mL). The levels of IL-6 and TNF-alpha in HMCL supernatants, protein, and mRNA expressions of PPARgamma in IL-1beta challenge cells were significantly increased more than those in untreated cells. Importantly, PPARgamma agonists troglitazone, rosiglitazone, and 15-deoxy-delta(12, 14)-prosglandin J2 significantly decreased the up expression of TNF-alpha and IL-6 in HMCL supernatants stimulated by IL-1beta. Furthermore, troglitazone downregulated TNF-alpha and IL-6 mRNA expression from IL-1beta challenge HMCLs. Our data suggest that PPARgamma plays an important role in mesangial cells responding to inflammatory stress. PPARgamma may prove to be a pharmacological target in glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526907     DOI: 10.1081/jdi-200031747

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  5 in total

1.  Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy.

Authors:  Kar Neng Lai; Loretta Y Y Chan; Hong Guo; Sydney C W Tang; Joseph C K Leung
Journal:  Pediatr Nephrol       Date:  2010-12-02       Impact factor: 3.714

2.  Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.

Authors:  Akizuki Morikawa; Kanaki Ishizeki; Yasunori Iwashima; Hiroki Yokoyama; Eiji Muto; Eiji Oshima; Masatomo Sekiguchi; Takanori Miura; Hiroshi Itoh; Masakazu Haneda
Journal:  Clin Exp Nephrol       Date:  2011-08-09       Impact factor: 2.801

Review 3.  PPAR-gamma agonists and diabetic nephropathy.

Authors:  Yahua Zhang; Youfei Guan
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

4.  PPAR-gamma agonists inhibit TGF-beta1-induced chemokine expression in human tubular epithelial cells.

Authors:  Wei-ming Wang; Hui-di Zhang; Yuan-meng Jin; Bing-bing Zhu; Nan Chen
Journal:  Acta Pharmacol Sin       Date:  2008-12-22       Impact factor: 6.150

Review 5.  Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications.

Authors:  Rishabh Hirawat; Mohd Aslam Saifi; Chandraiah Godugu
Journal:  Life Sci       Date:  2020-12-23       Impact factor: 6.780

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.